Biogen's LEQEMBI, a promising Alzheimer’s treatment, is expanding globally and received regulatory approval in Australia, Europe, China and 48 other countries. The new Alzheimer's Drug,
Leqembi, has shown continued success even after four years of use, according to a study. Biogen's stock has benefited from this success, showing a 18% return in a six-day gain streak and an increased buy rating from trusted sources such as Jefferies and RBC Capital.
Investment in Biogen has risen, with several firms such as Greenleaf and Swedbank increasing their stakes. The company is attempting to build manufacturing capability with a $2 Billion investment in North Carolina’s Research Triangle Park. It continues to target Alzheimer’s treatment with Tau-Targeting Therapy
BIIB080 receiving FDA Fast Track Designation. Despite, a temporary setback with FDA on High Dose Nusinersen Application, the firm is moving forward with strategic acquisitions like Massachusetts-based Alcyone Therapeutics for $85M. They are also moving deeper into Alczheimer's therapy with Eisai partnership and new LEQEMBI approval.
Biogen BIIB News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 04 Oct 2025 04:21:23 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -1
